Britain’s only breast implant manufacturer unveils latest generation of IMPLEO range
150 International Surgeons from 22 Countries Converge in London to Celebrate Breast of British
Read MoreAuthor: Balraj Juttla
Men and women seeking aesthetic treatments to boost career
New survey reveals Britons seek anti-aging treatments to stay competitive in work, reward themselves and maintain youthfulness
Read MoreAllergan successfully completes Kythera acquisition
KYBELLA® first FDA-approved non-surgical injection for submental fullness bolsters Allergan’s world-class facial aesthetics portfolio
Read MoreAllergan receives FDA approval to market JUVEDERM ULTRA XC for lip augmentation
Allergan announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip...
Read MoreNuMedii, Inc. and Allergan launch research alliance
NuMedii, Inc. have announced the formation of a research alliance with Allergan to explore new therapeutic options for the potential treatment of psoriasis. The companies will use NuMedii’s predictive Big (more…)
Read MoreNew method to aid dermal filler choice
With booming interest in dermal fillers for minimally invasive treatment of facial lines and wrinkles, plastic surgeons are looking for evidence to help them choose the product that will give (more…)
Read MoreFDA Approve Bayer’s Finacea® (azelaic acid) Foam, 15% for the Topical Treatment of Rosacea
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to (more…)
Read MoreBTL Vanquish receives FDA clearance for non-surgical circumferential reduction of the abdomen
BTL Industries, a manufacturer of devices for medical and aesthetic use, announced the FDA clearance of its groundbreaking BTL Vanquish device for circumferential reduction of the abdomen area. The system’s patented technology (more…)
Read MoreNovember/December 2025 Issue
